InvestorsHub Logo
Followers 8
Posts 450
Boards Moderated 0
Alias Born 10/04/2010

Re: Coolec78 post# 2852

Tuesday, 02/14/2017 11:40:08 PM

Tuesday, February 14, 2017 11:40:08 PM

Post# of 3833
They have a Phase 2 trial for Cirrhosis starting in Q2 2017, at which time NVTS will likely exercise their partnership option for Emricasan moving forward-they will be committing as much as $650M towards the eventual approval of the drug through Phase 3.

Once they announce the start of the Phase 2 trial the stock is likely to fly, I've been buying recently in the $5 range, I originally bought a bunch of shares at $2 after the GALT FX debacle in September

staccani has some great due diligence on this stock on the CNAT board if you are interested in doing some research
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News